Arvinas and Pfizer Report Promising Preliminary Data for Vepdegestrant and Abemaciclib Combo in ER+/HER2- Breast Cancer

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdege...

December 11, 2024 | Wednesday | News
Merck's KEYTRUDA® Combined with LYNPARZA® Achieves Key Milestone in Phase 3 Trial for Advanced Ovarian Cancer

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA ® (...

December 10, 2024 | Tuesday | News
Amgen’s BLINCYTO® Significantly Improves Disease-Free Survival in Pediatric B-ALL, Redefining Standard of Care

Amgen (NASDAQ:AMGN) announced new data demonstrating that adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease...

December 09, 2024 | Monday | News
Kite Presents Groundbreaking Real-World Data at ASH, Showcasing Yescarta®'s Impact on Relapsed/Refractory Large B-Cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), announced findings from three new analyses for Yescarta ® (axicabtagene ciloleucel) that demonstrate i...

December 09, 2024 | Monday | News
Agios Pharmaceuticals Announces Positive Phase 3 ENERGIZE-T Study Results for Mitapivat in Transfusion-Dependent Thalassemia

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases...

December 09, 2024 | Monday | News
Mexico Approves Eisai and Biogen’s LEQEMBI for Early Alzheimer’s Disease Treatment

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

December 09, 2024 | Monday | News
Pfizer to Showcase Latest Hematology and Breast Cancer Advancements at ASH and SABCS 2024

Pfizer Inc. (NYSE: PFE) will highlight the latest advancements from its growing hematology and breast cancer portfolios at the American Society of Hematolo...

December 09, 2024 | Monday | News
COFEPRIS Approves LEQEMBI® (Lecanemab) for Early Alzheimer's Disease in Mexico

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

December 09, 2024 | Monday | News
Zepbound® (Tirzepatide) Outperforms Wegovy® (Semaglutide) in Phase 3b SURMOUNT-5 Trial, Demonstrating Superior Weight Loss

Eli Lilly and Company (NYSE: LLY) announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound® ...

December 09, 2024 | Monday | News
FDA Accepts Roche's Supplemental Biologics License Application for Columvi® in Combination with GemOx for Relapsed or Refractory DLBCL

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics Licen...

December 09, 2024 | Monday | News
Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Partner to Advance Groundbreaking ALS Therapy

- Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying patholo...

December 05, 2024 | Thursday | News
OmniScience and INmune Bio Join Forces to Transform Global Alzheimer’s Trial Operations with GenAI-Powered Data Platform

OmniScience and INmune Bio announced a pioneering partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer&...

December 05, 2024 | Thursday | News
Thermo Fisher Launches Innovative CTS™ Detachable Dynabeads™ to Redefine T Cell Therapy Manufacturing

T cell isolation and controlled release delivers flexibility and control in process development, clinical trials and commercial manufacturing  Ther...

December 05, 2024 | Thursday | News
Philips and Mayo Clinic Partner to Enhance Cardiac MRI with AI to Improve Patient Experience and Operational Efficiency

Royal Philips (NYSE: PHG, AEX: PHIA) and Mayo Clinic announced a research collaboration aimed at advancing MRI for cardiac applications. Thr...

December 04, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close